<DOC>
	<DOCNO>NCT02308761</DOCNO>
	<brief_summary>TEN-010 small molecule , bromodomain extra-terminal domain ( BET ) bromodomain inhibitor . This study design characterize safety , tolerability , pharmacokinetics TEN-010 patient relapsed/refractory acute myeloid leukemia ( RR-AML ) hypomethylating agent ( HMA ) -refractory myelodysplastic syndrome ( MDS ) . In addition , trial ass response treatment use International Working Group ( IWG ) response criterion . This study conduct two part : dose escalation dose expansion . For dose escalation ( Part A ) , standard `` 3+3 '' design use successive cohort three patient RR-AML HMA-refractory MDS treat escalate dos maximum tolerate dose ( MTD ) identiﬁed . For dose expansion part study ( Part B ) , patient treat TEN-010 MTD ( high dose test MTD deﬁned ) characterize safety , pharmacokinetics , clinical response . A maximum 68 patient age 18 year old RR-AML HMA-refractory MDS enrol study . In part A , 18 adult patient enrol . This include 18 RR-AML HMA-refractory MDS patient enrol 3 dose level 6 patient . In part B , 50 patient RR-AML HMA-refractory MDS enrol separate study group 25 patient .</brief_summary>
	<brief_title>A Dose Escalation Cohort Expansion Study RO6870810/TEN-010 Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Relapsed/refractory acute myeloid leukemia ( AML ) Relapsed/refractory myelodysplastic syndrome ( MDS ) Subjects history allogeneic stem cell transplant eligible study participation provide follow eligibility criterion meet : 1 . Transplant &gt; 100 day prior study enrollment 2 . Subject take immunosuppressive medication least two week 3 . No sign symptom graft versus host disease Grade 1 skin involvement 4 . No active infection ECOG performance status &lt; =2 Life expectancy least 2 month Diseasefree active second/secondary prior malignancy &gt; =1 year exception currently treat basal cell squamous cell carcinoma skin , carcinoma insitu cervix breast Adequate hematological , renal , hepatic coagulation laboratory test result Women child bear potential men must agree use adequate contraception study 4 month last dose study drug Available duration study willing follow study procedure NYHA Class III IV , cardiac disease , myocardial infarction within past 6 month , unstable arrhythmia Have QTcF &gt; 470 msec ( female ) &gt; 450 ( male ) , history congenital long QT syndrome Uncontrolled bacterial , viral , fungal infection Known clinically important respiratory impairment Positive HIV , hepatitis B surface antigen , hepatitis C antibodies History major organ transplant Symptomatic CNS disease , malignancy , metastasis Pregnant nursing Concomitant chemotherapy , radiation therapy , immunotherapy , biologic therapy , hormonal therapy Treatment surgery chemotherapy within 21 day prior study entry Prior treatment small molecule ( BET ) family inhibitor Radiation symptomatic lesion within 14 day study enrollment Other exclusion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>